The Innovation and Value Initiative (IVI) appoints Patricia Deverka, MD, as its first Chief Science Officer.
ALEXANDRIA, Va., February 4, 2020 — The Innovation and Value Initiative (IVI), whose mission is to strengthen value assessment in healthcare that reflects its five principles of scientific rigor, transparency, patient centricity, innovation and market-based solutions, today announced that Patricia Deverka, MD, has joined the non-profit as its first Chief Science Officer. With close to 30 years of experience in the fields of health economics and outcomes research, health policy, stakeholder engagement and business development for corporations and non-profits alike, Dr. Deverka joins IVI from Geisinger National Precision Health, where she was the director for value evidence and outcomes. She is also a member of the National Human Genome Research Institute and National Advisory Council and has published on topics ranging from innovative technologies to patient engagement.
“We are excited to welcome Dr. Deverka to our team,” said Jennifer Bright, IVI’s executive director. “Her varied experience in health economics research, especially her work to meaningfully incorporate patient perspectives into clinical studies, are exactly the credentials that are needed to make a difference in the world of value assessment.”
For more on Dr. Deverka’s appointment, you can read the full press release.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Addressing the Bidirectional Impact of Schizophrenia and Substance Use Disorders
February 8th 2025Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and substance use disorders in an interview.
Read More